Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Deferred Taxes (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Deferred Taxes over the past 15 years, most recently at $109000.0 for Q4 2024.

For Q4 2024, Deferred Taxes rose 372.5% year-over-year to $109000.0; the TTM value through Nov 2024 reached $136000.0, down 66.5%, while the annual FY2024 figure was $163000.0, 54.34% down from the prior year.
Deferred Taxes for Q4 2024 was $109000.0 at Lifecore Biomedical, Inc. \De\, up from -$100000.0 in the prior quarter.
Over five years, Deferred Taxes peaked at $4.7 million in Q4 2020 and troughed at -$7.7 million in Q1 2021.
A 5-year average of -$849300.0 and a median of -$52000.0 in 2023 define the central range for Deferred Taxes.
On a YoY basis, Deferred Taxes climbed as much as 559.73% in 2020 and fell as far as 1774.2% in 2020.
Year by year, Deferred Taxes stood at $4.7 million in 2020, then plummeted by 160.4% to -$2.8 million in 2021, then surged by 100.14% to $4000.0 in 2022, then tumbled by 1100.0% to -$40000.0 in 2023, then skyrocketed by 372.5% to $109000.0 in 2024.
Business Quant data shows Deferred Taxes for LFCR at $109000.0 in Q4 2024, -$100000.0 in Q3 2024, and -$64000.0 in Q2 2024.